ACM
BLRX

ACT Capital Management’s BioLineRX BLRX Stock Holding History

ACT Capital Management’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$25K Hold
688
– – 0.03% 64
2022
Q2 		$35K Hold
688
– – 0.05% 69
2022
Q1 		$47K Hold
688
– – 0.05% 76
2021
Q4 		$56K Hold
688
– – 0.04% 85
2021
Q3 		$76K Hold
688
– – 0.04% 98
2021
Q2 		$78K Buy
+688
New +$80.9K 0.04% 100

Other funds holding BLRX

ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

ACT Capital Management's BLRX Position: Q3 2022 in Review

ACT Capital Management held its BioLineRX (BLRX) position steady in Q3 2022 at 688 shares worth $25K. The position accounts for 0.03% of the portfolio, ranked #64.

ACT Capital Management first reported a position in BLRX in Q2 2021 and has held it in 6 quarters since. The position peaked at $78K in Q2 2021. 28 funds tracked by Wall St. Rank hold BLRX as of Q3 2022.

  • ACT Capital Management held 688 shares of BioLineRX worth $25K as of Q3 2022.
  • ACT Capital Management left its BioLineRX share count unchanged in Q3 2022.
  • BioLineRX made up 0.03% of ACT Capital Management's portfolio in Q3 2022, its #64 holding.
  • ACT Capital Management first reported a position in BioLineRX in Q2 2021 and has held it in 6 quarters since.
  • ACT Capital Management's BioLineRX position peaked at $78K in Q2 2021.
  • 28 funds tracked by Wall St. Rank held BioLineRX as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.